2008
DOI: 10.1016/j.acthis.2007.06.002
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
26
0

Year Published

2008
2008
2018
2018

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 37 publications
(29 citation statements)
references
References 18 publications
3
26
0
Order By: Relevance
“…It has been reported to use these keratins as diagnostic markers with immunostaining (Chu and Weiss 2002) or as serological tumor markers to monitor cancer load, progression, and response to therapy (Linder 2007). Stathmin is a microtubule-destabilizing protein ubiquitously expressed in vertebrates and overexpressed in a variety of human malignancies (Kouzu et al 2006;Wei et al 2008). Studies have demonstrated that Stathmin expression correlates with hepatocarcinogenesis and tumor progression, and suggested that overexpression of this gene could predict early tumor recurrence and poor prognosis of hepatoma (Hsieh et al 2010;Gan et al 2010).…”
Section: Discussionmentioning
confidence: 94%
“…It has been reported to use these keratins as diagnostic markers with immunostaining (Chu and Weiss 2002) or as serological tumor markers to monitor cancer load, progression, and response to therapy (Linder 2007). Stathmin is a microtubule-destabilizing protein ubiquitously expressed in vertebrates and overexpressed in a variety of human malignancies (Kouzu et al 2006;Wei et al 2008). Studies have demonstrated that Stathmin expression correlates with hepatocarcinogenesis and tumor progression, and suggested that overexpression of this gene could predict early tumor recurrence and poor prognosis of hepatoma (Hsieh et al 2010;Gan et al 2010).…”
Section: Discussionmentioning
confidence: 94%
“…Differential expression of stathmin has repeatedly been described in various cancer types, such as leukaemia (Melhem et al 1991), lung adenocarcinoma (Chen et al 2003), oral squamous-cell carcinoma (Kouzu et al 2006), hepatocellular carcinoma (Yuan et al 2006), ovarian cancer (Wei et al 2008), breast cancer (Alli et al 2007bBrattsand 2000), Wilms tumours (Takahashi et al 2002), and glioblastoma multiforme (Ngo et al 2007). Stathmin overexpression was associated with poor outcome and a more malignant phenotype.…”
Section: Discussionmentioning
confidence: 95%
“…In hepatocellular carcinoma, elevated stathmin levels were accompanied by a more aggressive behaviour (Yuan et al 2006). Metastatic cases of ovarian cancer harboured higher levels of stathmin (Wei et al 2008). In a mouse glioblastoma multiforme model, stathmin was correlated with poor survival and resistance to nitrosourea compounds (Ngo et al 2007).…”
Section: Discussionmentioning
confidence: 96%
“…Many reports have shown that stathmin is overexpressed in a variety of human malignancies such as acute leukemia, breast carcinoma and lung cancer (Melhem et al 1997;Bièche et al 1998;Chen et al 2003). In our previous study, stathmin was also found to be overexpressed in osteosarcoma and ovarian carcinoma cells, and the overexpression of this gene signiWcantly correlated with prognosis of patients (Zhang et al 2004;Wei et al 2008). Moreover, we found that small interfering RNA (siRNA) or antisense-mediated downregulation of stathmin expression could lead to proliferation inhibition and chemosensitivity enhancement in human osteosarcoma cells (Zhang et al 2006;Wang et al 2007).…”
mentioning
confidence: 92%